MLYS · Nasdaq · CIK 0001933414

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 20, 2026. Its EDGAR record lists 56 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$154.7M
Form 4 filings on record, past 12 months
56

Company overview

Legal name (as filed)
Mineralys Therapeutics, Inc.
Ticker
MLYS
SEC Central Index Key (CIK)
0001933414
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
RADNOR, PA
State or country of incorporation
—
Fiscal year ends
December 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2036 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Mineralys Therapeutics, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$29.8MFY2022-$71.9MFY2023-$177.8MFY2024-$154.7MFY2025
MLYS annual results
ItemFY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue————
Net income-$29.8M-$71.9M-$177.8M-$154.7M
Diluted EPS-$5.77-$1.99-$3.66-$2.29
Total assets$114.4M$251.6M$205.9M$661.8M
Cash and equivalents$87.7M$49.3M$114.1M$172.9M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

MLYS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 12, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 19, 20268-KDirector or officer change· period Oct 16, 2026Document · Index
Apr 8, 2026DEF 14ADefinitive proxy statement· period May 21, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Mineralys Therapeutics, Inc., by form type:

144 ×184 ×143 ×38-K ×210-Q ×1SCHEDULE 13G/A ×1144/A ×1
MLYS recent filings
FiledFormWhat it isOriginal
Oct 20, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 19, 2026Document · Index
Oct 20, 20263Initial statement of beneficial ownership· period Oct 19, 2026Document · Index
Oct 20, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 19, 2026Document · Index
Oct 20, 20263Initial statement of beneficial ownership· period Oct 19, 2026Document · Index
Oct 19, 20268-KDirector or officer change· period Oct 16, 2026Document · Index
Oct 13, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Sep 30, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 24, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 22, 2026Document · Index
Sep 22, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 22, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026Document · Index
Sep 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 14, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 9, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 25, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 21, 2026Document · Index
Aug 21, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 17, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 13, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20263Initial statement of beneficial ownership· period Aug 10, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 20268-KResults of operations; Director or officer change· period Aug 5, 2026Document · Index
Aug 10, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 21, 2026Document · Index
Jul 21, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 20, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 17, 2026Document · Index
Jul 17, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 13, 2026Document · Index
Jul 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 13, 2026Document · Index
Jul 14, 2026144/A144/ADocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 9, 2026Document · Index
Jul 9, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

56 Form 4 filings appear in Mineralys Therapeutics, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Pennsylvania

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001933414 and XBRL company facts. Mineralys Therapeutics, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.